Table 6.

Body fat composition before and after re-installing SGAs in patients with schizophrenia during a 6-week treatment with quetiapine depending on the presence or absence of MetS [Me (Q1; Q3)].

Time-point for the assessment	Patients with MetS (n = 13)	p-value	Patients without MetS (n = 21)	p-value
Total body fat percentage
At hospitalization	41.2 [30; 47.2]	0.139	31.6 [24.6; 42.7]	0.003*
After a 6-week treatment	41.3 [30.6; 47.9]		32.2 [26.7; 42.1]
Visceral fat level
At hospitalization	10 [9; 14]	0.987	7 [4; 10]	0.020*
After a 6-week treatment	10 [9; 13]		7 [5; 11]
Total fat fold
At hospitalization, mm	122 [92; 150]	0.074	91 [67; 107]	0.007*
After a 6-week treatment, mm	127 [95; 154]		91 [73; 111]
Waist circumference
At hospitalization, cm	104 [101; 110]	0.233	88 [79; 96]	0.021*
After a 6-week treatment, cm	107 [100; 111]		89 [79; 97]
Body weight
At hospitalization, kg	97.0 [85.6; 111.7]	0.346	71.3 [61.1; 84.8]	<0.001*
After a 6-week treatment, kg	99.6 [84.4; 111.7]		74.6 [61.3; 85.8]
Body mass index
At hospitalization	32.2 [26.9; 37.6]	0.173	26.1 [22.1; 29.8]	<0.001*
After a 6-week treatment	32.6 [29.1; 38.4]		26.8 [22.8; 29.8]

*p < 0.05—statistically significant difference. Comparisons between groups were performed using the Wilcoxon signed-rank test.